Medline Inc. (MDLN) stock
MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 2/3066% above fair value
$39.47−0.51 (-1.28%)
Close on Nov 13, 2026Market cap $51.89BP/E –Yield –
Medline r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $80.00M, up 19.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.00M | +19.4% |
| FY2024 | Dec 31, 2024 | $67.00M | +11.7% |
| FY2023 | Dec 31, 2023 | $60.00M | – |
See a number that looks wrong?